This is a preview of subscription content, log in via an institution to check access.
Reference
Hannouf MB, et al. Cost Effectiveness of a 21-Gene Recurrence Score Assay Versus Canadian Clinical Practice in Post-Menopausal Women with Early-Stage Estrogen or Progesterone-Receptor-Positive, Axillary Lymph-Node Positive Breast Cancer. PharmacoEconomics : 28 Nov 2013. Available from: URL: http://dx.doi.org/10.1007/s40273-013-0115-9
Additional information
* Costs were presented in 2012 Canadian dollars, and included all treatment, and related management and surveillance costs over 7 years of follow up.
Rights and permissions
About this article
Cite this article
Oncotype DX likely to be cost effective in Canada. PharmacoEcon Outcomes News 693, 8 (2013). https://doi.org/10.1007/s40274-013-0939-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0939-8